Published in Lab Law Weekly, September 28th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Genta Incorporated.
Report 1: Genta Incorporated (NASDAQ:GNTAD) announced that it has received notice from the European Medicines Agency (EMEA) that the requested re-examination by the Committee for Medicinal Products for Human Use (CHMP) has reaffirmed a negative opinion for approval of the Company's marketing authorization application (MAA) for Genasense(R) (oblimersen). The MAA proposed the use of Genasense plus dacarbazine for treatment of patients with advanced melanoma. In its...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly